The regulation of electronic cigarettes has become one of the pillars of international health policy. On the one hand, the United States (USA) is moving towards models that differentiate risk profiles, prioritizing scientific evidence. But, on the other hand, several European countries that are tightening restrictions on vaping by taking different more general measures.
This contrast is more visible when two opposing movements are taken into account. The Food and Drug Administration (FDA), which is American Health, opens the door to certain flavors for adults, compared to Belgium’s decision to ban practically all flavors in these devices.
Tax advisors agree on personal income tax: “Not updating it violates the principle of economic capacity”
The Supreme Court confirms that the municipal capital gain can be claimed, but it is not enough to say that it was unconstitutional: it requires proving real losses in the sale of the property
The FDA is considering allowing flavors such as mint, coffee, tea or spices, including clove and cinnamon, in e-cigarettes intended for adult smokers. The agency keeps sweet or fruity flavors excluded since they have been linked to high consumption among minors.
The US agency proposes an individualized authorization system that goes product by product, supported by scientific reviews and under the legal criteria of public health protection.
Prevent the initiation of young people into nicotine
This approach strikes a complex balance between providing potentially less harmful alternatives for adult smokers and preventing young people from starting to use nicotine. The FDA maintains that only products that demonstrate net public health benefits should be authorized, especially if they help people quit traditional cigarettes without increasing consumption among adolescents.
The debate has gained relevance after the publication of various studies on the impact of flavors on smoking cessation processes. An investigation published in the magazine Internal and Emergency Medicine analyzed the behavior of 22,905 adult smokers in the United States for two years and concluded that users of electronic cigarettes with menthol flavor registered higher rates of complete tobacco abandonment than those who used traditional tobacco flavors. According to the study, the chances of quitting smoking increased between 11% and 15%.
The authors also maintain that the effect was especially significant among smokers of non-menthol cigarettes, a fact that, according to the researchers, reinforces the hypothesis that certain flavors can act as a transition tool towards abandoning combustible tobacco.
Belgium bans flavors in vaping
In Europe, however, the regulatory climate is moving in another direction. Belgium approved this week a ban on flavors in vaping that will only make tobacco or neutral flavored products available. The measure, which is part of the Belgian Government’s anti-smoking strategy, eliminates any flavor other than the traditional one from the market.
The decision has reignited debate over whether widespread ban policies could end up equating products with different risk profiles. Proponents of more flexible regulatory models argue that indiscriminately restricting all flavors could reduce the attractiveness of e-cigarettes as a replacement tool for adult smokers and indirectly favor the continuation of conventional tobacco consumption.
The discussion also acquires a community dimension in the midst of the review process of the European Directive on Tobacco Products (TPD). Various scientific and health sectors fear that future European regulations will adopt a line close to that promoted by Belgium.
Doctors and scientists support regulation based on scientific evidence
Along these lines, it must be considered that 26 European doctors and scientists have complained to the European Commission through a letter that they have ignored 131 scientific studies that confirm that electronic cigarettes or vapers, heated tobacco or nicotine bags are effective against smoking. The signatories warn against policies that, in their opinion, could oversimplify the health debate and hinder harm reduction strategies among adult smokers.
The background of the debate reflects an issue that is increasingly present in public health policies: how to make the protection of minors against new nicotine products compatible with the search for less harmful alternatives for millions of smokers. The United States seems to lean towards selective regulation supported by individualized scientific evaluations. Part of Europe, on the other hand, is approaching broader restriction models whose effectiveness and long-term consequences remain controversial.
FDA supports IQOS to be marketed as a modified risk product
The US FDA has renewed authorization of IQOS, Philip Morris’ heated tobacco device, as a modified risk tobacco product. The agency believes that completely replacing traditional cigarettes with this system significantly reduces exposure to harmful chemicals, thus supporting its potential as an alternative to smoking cessation.
The decision has international relevance because the FDA evaluates specific brands and not entire categories of products, so this recognition only affects IQOS. In addition, the US agency maintains that the available scientific evidence points to a probable reduction in diseases and mortality associated with conventional tobacco consumption.